US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Evommune

14.02

+0.45003.32%

Post-market: 14.020.00000.00%19:32 EDT

Volume:326.55K

Turnover:4.57M

Market Cap:508.82M

PE:-5.37

High:14.25

Open:13.74

Low:13.70

Close:13.57

52wk High:33.20

52wk Low:10.47

Shares:36.29M

Float Shares:19.98M

Volume Ratio:0.79

T/O Rate:1.63%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.6090

EPS(LYR):-11.2228

ROE:-52.11%

ROA:-31.99%

PB:1.83

PE(LYR):-1.25

Loading ...

Overview Company News Filings

Evommune price target lowered to $28 from $53 at Clear Street

Evommune Halts Urticaria Drug Development After Phase 2b Trial Fails Primary Goal, Shifts Focus to Dermatitis and Migraine

Top Midday Decliners

MT Newswires Live

Evommune Cut to Market Perform from Outperform by William Blair

Evommune Inc : Leerink Partners Cuts Target Price to $28 from $52

THOMSON REUTERS

Analysts Offer Insights on Healthcare Companies: Evommune, Inc. (EVMN) and Theravance Biopharma (TBPH)

Evommune Sinks as Skin Disease Drug Fails Mid-stage Trial

Evommune downgraded to Market Perform from Outperform at William Blair

Evommune Publishes Migraine Presentation on Mrgprx2 Antagonism

Evommune Inc : RBC Cuts Target Price to $30 from $50

THOMSON REUTERS

Evommune Halts EVO756 Urticaria Trial, Pipeline Advances

Evommune Says Evo756 Phase 2b Trial in Chronic Spontaneous Urticaria Misses Primary Endpoint

Evommune - to Report Evo756 Phase 2B Atopic Dermatitis Data in Q3 2026

THOMSON REUTERS

Evommune Announces Top-line Results from Evo756 Phase 2B Trial in Moderate-to-severe Chronic Spontaneous Urticaria

THOMSON REUTERS

Evommune - Initiates Screening for Evo756 Phase 2B Migraine Trial

THOMSON REUTERS

Evommune - to Continue Evo756 Development in Atopic Dermatitis and Migraine

THOMSON REUTERS

Evommune - Evo756 Phase 2B Csu Trial Did not Meet Primary Endpoint at 12 Weeks

THOMSON REUTERS

Evommune CEO Luis C. Pena Sells 7,438 Common Shares Worth $168,904.98

Apogee deal gives positive readthrough to Evommune pipeline, says Clear Street

Analysts Offer Insights on Healthcare Companies: Evommune, Inc. (EVMN), Immunome (IMNM) and Alcon (ALC)

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/EVMN/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"EVMN","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EVMN\",,,,,undefined,":{"symbol":"EVMN","market":"US","secType":"STK","nameCN":"Evommune","latestPrice":14.02,"timestamp":1787342400000,"preClose":13.57,"halted":0,"volume":326552,"hourTrading":{"tag":"盘后","latestPrice":14.02,"preClose":14.02,"latestTime":"19:32 EDT","volume":5950,"amount":83404.12,"timestamp":1787355127959,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.033161385408990364,"floatShares":19982000,"shares":36292113,"eps":-2.609,"marketStatus":"Market Closed","change":0.45,"latestTime":"08-21 16:00:00 EDT","open":13.74,"high":14.25,"low":13.7,"amount":4565526.77752,"amplitude":0.040531,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-2.609,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1787558400000},"marketStatusCode":7,"adr":0,"listingDate":1762405200000,"exchange":"NYSE","adjPreClose":13.57,"preHourTrading":{"tag":"盘前","latestPrice":13.74,"preClose":13.57,"latestTime":"07:51 EDT","volume":1,"amount":13.74,"timestamp":1787313097952,"change":0.17,"changeRate":0.012528,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":14.02,"preClose":14.02,"latestTime":"19:32 EDT","volume":5950,"amount":83404.12,"timestamp":1787355127959,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.7864220387572776,"impliedVol":1.4355,"impliedVolPercentile":0.6905},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EVMN\",,,,,undefined,":{"symbol":"EVMN","floatShares":19982000,"roa":"-31.99%","roe":"-52.11%","lyrEps":-11.222761,"volumeRatio":0.7864220387572776,"shares":36292113,"dividePrice":0,"high":14.25,"amplitude":0.040531,"preClose":13.57,"low":13.7,"week52Low":10.47,"pbRate":"1.83","psRate":"50.88","week52High":33.2,"institutionHeld":0,"latestPrice":14.02,"eps":-2.609,"divideRate":0,"volume":326552,"delay":0,"ttmEps":-2.609,"open":13.74,"prevYearClose":17.12,"prevWeekClose":14.65,"prevMonthClose":11.25,"prevQuarterClose":13.29,"fiveDayClose":14.65,"twentyDayClose":11.36,"sixtyDayClose":23.34},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/EVMN\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-06","symbol":"EVMN","fiscalQuarterEnding":"2026/06","expectedEps":-0.68,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1785988800000,"reportTimeType":"post","actualEps":-0.89},{"market":"US","date":"2026-05-07","symbol":"EVMN","fiscalQuarterEnding":"2026/03","expectedEps":-0.83,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1778126400000,"reportTimeType":"post","actualEps":-0.64},{"market":"US","date":"2026-03-05","symbol":"EVMN","fiscalQuarterEnding":"2025/12","expectedEps":-0.82,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1772686800000,"reportTimeType":"post","actualEps":-1.43}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"EVMN\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"EVMN\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.2727,"buy":0.5455,"hold":0.1818,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5455,"analysts":11,"updateTime":1782878400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/EVMN\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"EVMN","date":"2026-08-21","current":-5.373706,"percent":0.994975,"low":-16.229076,"twenty":-12.450318,"median":-9.782121,"eighty":-7.430686,"high":-5.090694,"avg":-9.990083,"sd":2.778399,"marketCap":492483973},"quantilePoints":[{"date":"2025-11-07","current":-9.395174,"twenty":-7.823584,"median":-7.430686,"eighty":-7.430686,"marketCap":608469038},{"date":"2025-11-14","current":-8.461694,"twenty":-9.04686,"median":-8.505813,"eighty":-7.430686,"marketCap":548013143},{"date":"2025-11-21","current":-8.689259,"twenty":-9.04686,"median":-8.689259,"eighty":-7.430686,"marketCap":562751147},{"date":"2025-11-28","current":-9.618094,"twenty":-9.051504,"median":-8.707835,"eighty":-8.049291,"marketCap":622906267},{"date":"2025-12-05","current":-10.184684,"twenty":-9.618094,"median":-8.986487,"eighty":-8.483986,"marketCap":659600890},{"date":"2025-12-12","current":-9.657505,"twenty":-9.633858,"median":-9.000419,"eighty":-8.483986,"marketCap":592227156},{"date":"2025-12-19","current":-7.716136,"twenty":-9.618094,"median":-8.986487,"eighty":-8.244704,"marketCap":473176635},{"date":"2025-12-26","current":-9.042428,"twenty":-9.528926,"median":-9.016673,"eighty":-8.355807,"marketCap":554508795},{"date":"2026-01-02","current":-8.800817,"twenty":-9.392482,"median":-9.003431,"eighty":-8.469125,"marketCap":539692472},{"date":"2026-01-09","current":-9.37143,"twenty":-9.380689,"median":-8.972554,"eighty":-8.293747,"marketCap":574684215},{"date":"2026-01-16","current":-10.075701,"twenty":-9.649623,"median":-9.019686,"eighty":-8.354639,"marketCap":617872222},{"date":"2026-01-23","current":-9.710714,"twenty":-9.690151,"median":-9.037572,"eighty":-8.461694,"marketCap":595490116},{"date":"2026-01-30","current":-11.129537,"twenty":-9.775997,"median":-9.042428,"eighty":-8.498847,"marketCap":682496613},{"date":"2026-02-06","current":-8.564346,"twenty":-9.775997,"median":-9.064213,"eighty":-8.549933,"marketCap":525191389},{"date":"2026-02-13","current":-14.332171,"twenty":-9.885497,"median":-9.065437,"eighty":-8.563866,"marketCap":878891712},{"date":"2026-02-20","current":-14.769127,"twenty":-10.094711,"median":-9.253195,"eighty":-8.56425,"marketCap":905687191},{"date":"2026-02-27","current":-13.689588,"twenty":-10.579486,"median":-9.338016,"eighty":-8.621921,"marketCap":839486596},{"date":"2026-03-06","current":-11.484529,"twenty":-11.200535,"median":-9.381712,"eighty":-8.67867,"marketCap":790939493},{"date":"2026-03-13","current":-12.018327,"twenty":-12.245567,"median":-9.479385,"eighty":-8.689259,"marketCap":827702188},{"date":"2026-03-20","current":-12.321662,"twenty":-12.396972,"median":-9.618094,"eighty":-8.70412,"marketCap":848592844},{"date":"2026-03-27","current":-12.379191,"twenty":-12.362455,"median":-9.695292,"eighty":-8.728757,"marketCap":852554865},{"date":"2026-04-02","current":-11.725452,"twenty":-12.336306,"median":-9.710846,"eighty":-8.771001,"marketCap":807531900},{"date":"2026-04-10","current":-14.983685,"twenty":-12.570606,"median":-9.775997,"eighty":-8.798761,"marketCap":1031926357},{"date":"2026-04-17","current":-14.000462,"twenty":-13.015147,"median":-9.975459,"eighty":-8.828576,"marketCap":964211818},{"date":"2026-04-24","current":-13.514081,"twenty":-13.425068,"median":-10.075701,"eighty":-8.877926,"marketCap":930714732},{"date":"2026-05-01","current":-12.44718,"twenty":-13.370677,"median":-10.26642,"eighty":-8.898489,"marketCap":857237253},{"date":"2026-05-08","current":-11.767292,"twenty":-13.351187,"median":-10.76455,"eighty":-8.934568,"marketCap":810413370},{"date":"2026-05-15","current":-10.76944,"twenty":-13.300701,"median":-10.81684,"eighty":-8.966981,"marketCap":818337411},{"date":"2026-05-22","current":-11.162865,"twenty":-13.208546,"median":-10.76944,"eighty":-8.989273,"marketCap":848232660},{"date":"2026-05-29","current":-11.058584,"twenty":-13.135327,"median":-10.864241,"eighty":-9.002829,"marketCap":840308618},{"date":"2026-06-05","current":-9.807205,"twenty":-13.084182,"median":-10.80499,"eighty":-9.017037,"marketCap":745220116},{"date":"2026-06-12","current":-9.807205,"twenty":-13.030837,"median":-10.755219,"eighty":-9.036643,"marketCap":745220116},{"date":"2026-06-18","current":-9.788245,"twenty":-12.946112,"median":-10.53322,"eighty":-9.042258,"marketCap":743779381},{"date":"2026-06-26","current":-11.43779,"twenty":-12.867664,"median":-10.624868,"eighty":-9.042428,"marketCap":869123316},{"date":"2026-07-02","current":-6.07677,"twenty":-12.855112,"median":-10.547048,"eighty":-9.032928,"marketCap":461755529},{"date":"2026-07-10","current":-6.403835,"twenty":-12.813273,"median":-10.376014,"eighty":-8.958621,"marketCap":486608205},{"date":"2026-07-17","current":-5.550622,"twenty":-12.635456,"median":-10.177718,"eighty":-8.800817,"marketCap":421775136},{"date":"2026-07-24","current":-5.36576,"twenty":-12.598847,"median":-10.075701,"eighty":-8.689259,"marketCap":407727971},{"date":"2026-07-31","current":-5.37998,"twenty":-12.561192,"median":-10.06542,"eighty":-8.56425,"marketCap":408808522},{"date":"2026-08-07","current":-5.090694,"twenty":-12.489019,"median":-9.881902,"eighty":-8.43493,"marketCap":481925817},{"date":"2026-08-14","current":-5.393903,"twenty":-12.464961,"median":-9.807205,"eighty":-8.177768,"marketCap":510630029},{"date":"2026-08-21","current":-5.202222,"twenty":-12.450318,"median":-9.782121,"eighty":-7.430686,"marketCap":492483973}],"updateTime":1787507876686},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"EVMN\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2647302943","title":"Evommune price target lowered to $28 from $53 at Clear Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2647302943","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647302943?lang=en_us&edition=fundamental","pubTime":"2026-06-30 04:20","pubTimestamp":1782764455,"startTime":"0","endTime":"0","summary":"Clear Street lowered the firm’s price target on Evommune (EVMN) to $28 from $53 and keeps a Buy rating on the shares after the company announced th...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/evommune-price-target-lowered-to-28-from-53-at-clear-street-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/evommune-price-target-lowered-to-28-from-53-at-clear-street-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EVMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1151653547","title":"Evommune Halts Urticaria Drug Development After Phase 2b Trial Fails Primary Goal, Shifts Focus to Dermatitis and Migraine","url":"https://stock-news.laohu8.com/highlight/detail?id=1151653547","media":"Deep News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1151653547?lang=en_us&edition=fundamental","pubTime":"2026-06-30 03:50","pubTimestamp":1782762639,"startTime":"0","endTime":"0","summary":"The biotechnology firm Evommune announced top-line results from a Phase 2b clinical trial of EVO756 for moderate-to-severe chronic spontaneous urticaria on Monday, revealing the study did not meet...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EVMN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647309875","title":"Top Midday Decliners","url":"https://stock-news.laohu8.com/highlight/detail?id=2647309875","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647309875?lang=en_us&edition=fundamental","pubTime":"2026-06-30 01:49","pubTimestamp":1782755397,"startTime":"0","endTime":"0","summary":"Evommune's  top-line results from a phase 2b trial of EVO756 to treat adults with moderate-to-severe chronic spontaneous urticaria failed to meet the primary endpoint at any dosage, according to a statement released Monday.Shares sank 39% as intraday trading volume surged to over 5.9 million from a daily average of about 415,000.Solidion Technology  said Monday it plans to opportunistically acquire shares of SpaceX  as a long-term strategic treasury asset, using a modest portion of its cash reserves.Shares of Solidion slumped 20%, with intraday trading volume climbing to about 2.4 million from a daily average of roughly 2.8 million.Martin Marietta Materials  agreed to combine with limestone supplier Lhoist North America in a $13.5 billion deal.Shares dropped 6.6% as intraday trading volume rose to more than 759,300 from a daily average of about 509,000.Price: 15.35, Change: -9.83, Percent Change: -39.04","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4585","SPAL","ES3.SI","SPCQ","BK4548","BK4096","LU0300736492.USD","SSPC","BK4588","BK4011","G3B.SI","SPAX","SPCX","LU0300736062.USD","SPCM","EVMN","SPCG","SNK","LOFF","LU2237438978.USD","LU0053666078.USD","SG9999001077.SGD","MLM.AU","STI","STI.SI","SPCH","GAB.SI","BK4089","BK4139","MLM","BK7095","SPCU","SPCF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647306334","title":"Evommune Cut to Market Perform from Outperform by William Blair","url":"https://stock-news.laohu8.com/highlight/detail?id=2647306334","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647306334?lang=en_us&edition=fundamental","pubTime":"2026-06-30 01:01","pubTimestamp":1782752460,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/EVMN/analyst-ratings(END) Dow Jones NewswiresJune 29, 2026 13:01 ET","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EVMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647370102","title":"Evommune Inc : Leerink Partners Cuts Target Price to $28 from $52","url":"https://stock-news.laohu8.com/highlight/detail?id=2647370102","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647370102?lang=en_us&edition=fundamental","pubTime":"2026-06-29 22:35","pubTimestamp":1782743711,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260629:nFWN4310V2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["EVMN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647670377","title":"Analysts Offer Insights on Healthcare Companies: Evommune, Inc. (EVMN) and Theravance Biopharma (TBPH)","url":"https://stock-news.laohu8.com/highlight/detail?id=2647670377","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647670377?lang=en_us&edition=fundamental","pubTime":"2026-06-29 21:50","pubTimestamp":1782741008,"startTime":"0","endTime":"0","summary":"Analysts fell to the sidelines weighing in on Evommune, Inc. (EVMN) and Theravance Biopharma (TBPH) with neutral ratings, indicating that the exper...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-evommune-inc-evmn-and-theravance-biopharma-tbph-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-evommune-inc-evmn-and-theravance-biopharma-tbph-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4581","LU0029874061.USD","BK4588","XLV","HCSG","XBI","BK4139","BK4007","BK4137","LU0128526141.USD","EVMN","LABU","TBPH","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647372007","title":"Evommune Sinks as Skin Disease Drug Fails Mid-stage Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2647372007","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647372007?lang=en_us&edition=fundamental","pubTime":"2026-06-29 21:47","pubTimestamp":1782740844,"startTime":"0","endTime":"0","summary":"BUZZ-Evommune sinks as skin disease drug fails mid-stage trial** Shares of drug developer EvommuneEVMN.Nfall 32% to over four-month low of $17.10** Co says its experimental pill, EVO756, did not reduce hive activity scores significantly better than a placebo after 12 weeks, failing to meet the main goal of a mid-stage trial** Co was testing the drug in patients with moderate-to-severe chronic spontaneous urticaria, commonly known as chronic hives, which causes recurring itchy welts on the skin that can last for months or years and significantly disrupt daily life** RBC Capital Markets analysts cut Evommune's PT to $30 from $50 and said the research firm believes \"the issue is more likely the indication rather than the drug or mechanism\"** EVO756 works by blocking the MRGPRX2 receptor on mast cells, a pathway involved in triggering inflammation and itch** The trial enrolled 160 patients who had not responded to standard antihistamines** Co says it plans to continue development of EVO756","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260629:nL4N43114C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EVMN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647377951","title":"Evommune downgraded to Market Perform from Outperform at William Blair","url":"https://stock-news.laohu8.com/highlight/detail?id=2647377951","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647377951?lang=en_us&edition=fundamental","pubTime":"2026-06-29 21:40","pubTimestamp":1782740441,"startTime":"0","endTime":"0","summary":"William Blair downgraded Evommune (EVMN) to Market Perform from Outperform without a price target after the company announced that the Phase IIb st...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/evommune-downgraded-to-market-perform-from-outperform-at-william-blair-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/evommune-downgraded-to-market-perform-from-outperform-at-william-blair-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EVMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647372957","title":"Evommune Publishes Migraine Presentation on Mrgprx2 Antagonism","url":"https://stock-news.laohu8.com/highlight/detail?id=2647372957","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647372957?lang=en_us&edition=fundamental","pubTime":"2026-06-29 21:25","pubTimestamp":1782739518,"startTime":"0","endTime":"0","summary":"Evommune publishes migraine presentation on MRGPRX2 antagonismEvommune published a medical research presentation outlining MRGPRX2 antagonism as a potential migraine approach targeting meningeal mast ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260629:nNDL83sMQ6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EVMN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647937266","title":"Evommune Inc : RBC Cuts Target Price to $30 from $50","url":"https://stock-news.laohu8.com/highlight/detail?id=2647937266","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647937266?lang=en_us&edition=fundamental","pubTime":"2026-06-29 21:24","pubTimestamp":1782739476,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260629:nFWN4310OE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","EVMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647741253","title":"Evommune Halts EVO756 Urticaria Trial, Pipeline Advances","url":"https://stock-news.laohu8.com/highlight/detail?id=2647741253","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647741253?lang=en_us&edition=fundamental","pubTime":"2026-06-29 20:59","pubTimestamp":1782737952,"startTime":"0","endTime":"0","summary":"Evommune, Inc. ( ($EVMN) ) has shared an update. On June 29, 2026, Evommune reported top-line results from a randomized, double-blind, placebo-cont...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/evommune-halts-evo756-urticaria-trial-pipeline-advances?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/evommune-halts-evo756-urticaria-trial-pipeline-advances?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EVMN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647371114","title":"Evommune Says Evo756 Phase 2b Trial in Chronic Spontaneous Urticaria Misses Primary Endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2647371114","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647371114?lang=en_us&edition=fundamental","pubTime":"2026-06-29 20:30","pubTimestamp":1782736237,"startTime":"0","endTime":"0","summary":"Evommune says EVO756 Phase 2b trial in chronic spontaneous urticaria misses primary endpointEvommune reported top-line Phase 2b results for oral EVO756 in chronic spontaneous urticaria.The trial misse","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260629:nNDL9jF3qF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","EVMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647937110","title":"Evommune - to Report Evo756 Phase 2B Atopic Dermatitis Data in Q3 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2647937110","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647937110?lang=en_us&edition=fundamental","pubTime":"2026-06-29 20:30","pubTimestamp":1782736200,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260629:nTUA71MCCQ:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["EVMN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647371940","title":"Evommune Announces Top-line Results from Evo756 Phase 2B Trial in Moderate-to-severe Chronic Spontaneous Urticaria","url":"https://stock-news.laohu8.com/highlight/detail?id=2647371940","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647371940?lang=en_us&edition=fundamental","pubTime":"2026-06-29 20:30","pubTimestamp":1782736200,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260629:nTUA71MCCQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["EVMN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647371174","title":"Evommune - Initiates Screening for Evo756 Phase 2B Migraine Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2647371174","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647371174?lang=en_us&edition=fundamental","pubTime":"2026-06-29 20:30","pubTimestamp":1782736200,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260629:nTUA71MCCQ:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","EVMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647371173","title":"Evommune - to Continue Evo756 Development in Atopic Dermatitis and Migraine","url":"https://stock-news.laohu8.com/highlight/detail?id=2647371173","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647371173?lang=en_us&edition=fundamental","pubTime":"2026-06-29 20:30","pubTimestamp":1782736200,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260629:nTUA71MCCQ:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","EVMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647160371","title":"Evommune - Evo756 Phase 2B Csu Trial Did not Meet Primary Endpoint at 12 Weeks","url":"https://stock-news.laohu8.com/highlight/detail?id=2647160371","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647160371?lang=en_us&edition=fundamental","pubTime":"2026-06-29 20:30","pubTimestamp":1782736200,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260629:nTUA71MCCQ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["EVMN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646842938","title":"Evommune CEO Luis C. Pena Sells 7,438 Common Shares Worth $168,904.98","url":"https://stock-news.laohu8.com/highlight/detail?id=2646842938","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646842938?lang=en_us&edition=fundamental","pubTime":"2026-06-25 08:00","pubTimestamp":1782345623,"startTime":"0","endTime":"0","summary":"Evommune CEO Luis C. Pena sells 7,438 common shares worth $168,904.98Evommune President, CEO, director Luis C. Pena sold 7,438 common shares on June 22, 2026.Sale priced at a weighted average of USD 2","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260625:nNDL1C0T6M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Evommune CEO Luis C. Pena Sells 7,438 Common Shares Worth $168,904.98","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","EVMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645038980","title":"Apogee deal gives positive readthrough to Evommune pipeline, says Clear Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2645038980","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645038980?lang=en_us&edition=fundamental","pubTime":"2026-06-23 05:55","pubTimestamp":1782165309,"startTime":"0","endTime":"0","summary":"Clear Street reiterated a Buy rating and $53 price target on Evommune (EVMN), saying Abbvie’s (ABBV) proposed acquisition of Apogee (APGE) provides...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/apogee-deal-gives-positive-readthrough-to-evommune-pipeline-says-clear-street-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/apogee-deal-gives-positive-readthrough-to-evommune-pipeline-says-clear-street-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1732800096.USD","LU0098860793.USD","LU1934455194.USD","LU1989771016.USD","LU0203345920.USD","LU0820561909.HKD","SG9999011175.SGD","IE0009355771.USD","LU1585245621.USD","ABBV","LU0689626769.HKD","LU0820561818.USD","LU0861579265.USD","LU1551013425.SGD","LU0211328371.USD","BK4139","LU2023251221.USD","EVMN","LU2237443465.HKD","BK4581","LU1989772840.SGD","LU0211327993.USD","LU2129689431.USD","LU2089283258.USD","LU1934455277.USD","LU1267930490.SGD","LU2347655156.SGD","LU0965509010.AUD","BK4534","IE000BZT7R73.USD","IE0002141913.USD","LU0912757837.SGD","IE00BJJMRZ35.SGD","LU1291159041.SGD","LU0859254822.USD","LU1989772923.USD","APGE","LU1839511570.USD","IE0004445239.USD","LU0256863811.USD","LU0057025933.USD","LU1244550221.USD","LU1496350171.SGD","IE00BSNM7G36.USD","LU0661504455.SGD","LU2357627491.SGD","LU0472753341.HKD","LU1244550577.SGD","LU0203347892.USD","IE00BJT1NW94.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642026057","title":"Analysts Offer Insights on Healthcare Companies: Evommune, Inc. (EVMN), Immunome (IMNM) and Alcon (ALC)","url":"https://stock-news.laohu8.com/highlight/detail?id=2642026057","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642026057?lang=en_us&edition=fundamental","pubTime":"2026-06-12 19:31","pubTimestamp":1781263876,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Evommune, Inc. (EVMN), Immunome (IMNM) and Alcon (AL...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-evommune-inc-evmn-immunome-imnm-and-alcon-alc-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-evommune-inc-evmn-immunome-imnm-and-alcon-alc-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XLV","ALC","EVMN","LU0029874061.USD","BK4585","BK4198","LU1804176565.USD","XBI","BK4139","BK4581","BK4588","LABU","LU2265009873.SGD","BK4137","HCSG","BK4534","IMNM","LU0128526141.USD","BK4563"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":2,"totalSize":84,"code":"91000000","status":"200"}]}}